BridgeBio Pharma 2025 Q2 Earnings Deepened Losses Amid Record Revenue Growth

BridgeBio Pharma reported Q2 2025 earnings with a significant increase in revenue but a deepened net loss. The company exceeded expectations in revenue growth, driven by its commercial product Attruby, while its losses widened compared to the prior year. The company has not adjusted its guidance in the report.

Revenue
BridgeBio's total revenue surged to $110.6 million in Q2 2025, a 4999.9% increase from $2.17 million in Q2 2024. This growth was primarily fueled by $71.5 million in U.S. Attruby net product revenue, complemented by $37.5 million in license and services revenue and $1.6 million in royalty revenue. The revenue increase was attributed to the expanding adoption of Attruby in treatment centers and community practices, with nearly 4,000 unique prescriptions issued by August 1, 2025.

Earnings/Net Income
Net losses for the quarter expanded to $183.76 million, or $0.95 per share, compared to $75.54 million, or $0.39 per share, in the same period the previous year. The net loss per share increased by 143.6%, marking the fifth consecutive year of losses during this period. The company continues to face financial challenges despite its robust revenue growth.

Price Action
BridgeBio’s stock price showed a positive response in the short term, with a 3.71% rise on the latest trading day, a 6.24% increase for the week, and an 11.87% gain for the month. This reflects investor confidence in the company’s recent performance and future pipeline developments.

Post Earnings Price Action Review
A strategy of purchasing BridgeBio shares following a revenue growth quarter has historically shown strong performance. Over the past three years, this approach generated a 264.87% return, outpacing the benchmark by 216.28%. While the Sharpe ratio of 0.70 indicates reasonable risk-adjusted returns, the strategy is marked by high volatility (80.85%) and a zero maximum drawdown. Investors should consider the potential for significant short-term fluctuations when adopting this approach.

CEO Commentary
Neil Kumar, Ph.D., CEO and Founder, emphasized the momentum of Attruby’s launch and its impact on patients with ATTR-CM. He also highlighted the importance of the upcoming Phase 3 trial readouts for ADH1, LGMD2I/R9, and achondroplasia, which could solidify BridgeBio's position as a leader in genetic disease treatment. Kumar expressed confidence that these programs will build on Attruby’s success and diversify the company’s portfolio.

Guidance
BridgeBio has not provided specific financial guidance for the remainder of the year in its earnings report. However, the company remains focused on executing its commercial strategy and delivering topline results from key clinical trials.

Additional News
BridgeBio received $300 million from the partial sale of royalties on BEYONTTRA sales in Europe and a $30 million milestone payment from Alexion related to the Japan approval of BEYONTTRA. The company ended the quarter with $756.9 million in cash, providing strong financial resources to support its ongoing operations and clinical programs. Pipeline developments include topline results expected from the FORTIFY Phase 3 study of BBP-418 for LGMD2I/R9 in fall 2025 and the PROPEL 3 Phase 3 study of infigratinib for achondroplasia in early 2026. Additionally, enrollment is expected to complete for the ACCEL 2/3 Phase 2 study of infigratinib for hypochondroplasia by the end of 2025.